Crossfire Network

Crossfire Therapeutics is a biotechnology company focused on developing a new generation of highly selective antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company's proprietary Crossfire platform utilizes a unique mechanism of action that enables the selective release of potent payloads within the tumor microenvironment, aiming to overcome the toxicity and efficacy limitations of traditional ADCs. By leveraging advanced linker-payload chemistry and novel targeting strategies, Crossfire seeks to expand the therapeutic window for cancer treatments. The company is currently advancing a pipeline of pre-clinical programs targeting high-value oncology indications.